Endocrinology Archives - Corcept Therapeutics

Prevalence and Clinical Impact of Hypercortisolism in Patients With Resistant Hypertension: Primary Results From the MOMENTUM Study

March 28, 2026

Bhatt et al. • 2026 • ACC.26

Efficacy and Safety of Relacorilant for the Treatment of Patients With Cushing’s Syndrome (GRACE): A Multicentre, Phase 3, Double-Blind, Placebo-Controlled, Randomised-Withdrawal Study

February 20, 2026

Pivonello • 2026 • The Lancet Diabetes & Endocrinology

Mifepristone, a Glucocorticoid Receptor Antagonist, Reduced HbA1c and Body Weight in Difficult-to-control Type 2 Diabetes with Hypercortisolism: The CATALYST Prevalence and Treatment Trial

September 17, 2025

DeFronzo, et al. • 2025 • EASD 2025

Difficult-to-Control Type 2 Diabetes and a Post-Dexamethasone Suppression Test Cortisol of 1.2–1.8 µg/dL: Findings From a Large Prospective Study

September 17, 2025

Buse, et al. • 2025 • EASD 2025

Final Results of the CATALYST Trial

August 8, 2025

Dr. Katia Sloan • 2025 • ADCES

Characterization of Individuals With Difficult-to-Control Type 2 Diabetes and Post-Dexamethasone Suppression Test Cortisol Values <1.2, 1.2–1.8, and >1.8 μg/dL: Findings From the CATALYST Part 1 Study

July 14, 2025

Auchus et al. • 2025 • ENDO 2025

The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension

July 14, 2025

Einhorn et al. • 2025 • ENDO 2025

Effects of Relacorilant on Body Weight and Body Composition in Patients With Endogenous Hypercortisolism in the Phase 3 GRACE and GRADIENT Studies

July 13, 2025

Hamidi et al. • 2025 • ENDO 2025

Efficacy and Safety of Relacorilant in Individuals With Adrenal Hypercortisolism: Results From the Phase 3 GRACE and GRADIENT Studies

July 13, 2025

Badiu et al. • 2025 • ENDO 2025

Effects of Relacorilant on Pituitary Tumor Volume in Patients With Cushing Disease: Results From the Phase 3 GRACE Study

July 10, 2025

Dobri et al. • 2025 • International Pituitary Congress